Drug Safety Update

Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension

Issued 21 Jul 2026

Read and act on the official notice on GOV.UK

The MHRA's summary

The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episodes of severe hypertension.

MHRA's audience tags: Cardiovascular disease lipidology, Emergency medicine, Endocrinology diabetology metabolism, General practice, Gi hepatology pancreatic disorders, Haematology, Pharmacy

Pharmshark is not an official alerting route. Make sure your pharmacy receives alerts directly from the MHRA and through your organisation, and always act on the official GOV.UK notice.

Source: the MHRA on GOV.UK. Contains public sector information licensed under the Open Government Licence v3.0. Pharmshark is not affiliated with or endorsed by the MHRA.